These are the coronavirus stories you need to know about today.

In the 100 days since the U.S. reported its first coronavirus case, we've had more than 1.2 million cases and 73,000 deaths. But are things getting any better?

If it feels like all your internal clocks are melting as your stay-at-home days drone on, you are not alone. Researchers say that people in various levels of COVID-19 quarantine around the world are reporting a distorted sense of time.

Based on a review of more than 1,000 patients who've already sought care for respiratory illnesses since the coronavirus was declared a pandemic in March, researchers at Harvard Medical School are offering up a new list of symptoms to watch out for.

A roundup of the latest news about COVID-19

These are the coronavirus stories you need to know about today.

A child psychologist advises parents to address the threat of internet challenges with continual, preemptive conversations with kids -- and with special phone settings.

Title: New Cholesterol Drug Approved by FDA
Category: Health News
Created: 2/24/2020 12:00:00 AM
Last Editorial Review: 2/24/2020 12:00:00 AM

Canada is soon expected to join the international effort to provide access to health research through the PMC International network of digital archives. PMC Canada is the result of a three-way collaborative effort by the National Library of Medicine (NLM), the Canadian Institutes of Health Research (CIHR), and the National Research Council's Canada Institute for Scientific and Technical Information (NRC-CISTI). Similar to UK PubMed Central, PMC Canada will include most of the health and life sciences literature available through the U.S. PMC. PMC Canada will also include research resulting from funding through the Canadian Institutes of Health Research (CIHR). Components of the new repository will include a bilingual interface as well a manuscript submission system for CIHR researchers.

The newest addition to the PMC International effort, PubMed Central Canada has now been made public. Stay tuned for the launch of PMC Canada's manuscript submission system later this year.

The PMC Canada manuscript submission system was released on April 28, 2010. The system will enable researchers funded by the Canadian Institutes of Health Research to deposit their peer-reviewed research publications, in compliance with CIHR's Policy on Access to Research Outputs.

The third annual Journal Article Tag Suite Conference (JATS-Con) will be held on October 16 and 17, 2012 on the NIH Campus in Bethesda, Maryland. JATS-Con is a conference for users of the NISO Z39.96 Journal Article Tag Suite: that is, users of any of the NLM DTDs. JATS-Con is a peer-reviewed conference with a broad range of content on the Tag Suite from the technical to publishing theory — and the latest news on the Tag Suite. For more information, see JATS-Con.

The Journal Archiving Tag Suite(JATS), known formerly as the NLM DTD, has now been officially adopted as an American National Standards Institute (ANSI)/ National Information Standards Organization (NISO) standard. According to the press release from NISO, "JATS provides a common XML format in which publishers and archives can exchange journal content by preserving the intellectual content of journals independent of the form in which that content was originally delivered." For more information, see NISO Publishes Journal Article Tag Suite (JATS) Standard.

The PMC Overview and FAQ have been updated to provide more information on the Scientific Quality Review Process for journals that apply to participate in PMC.

In 2014, PMC implemented a scientific and editorial quality review procedure whereby expert consultants from outside the National Library of Medicine (NLM) conduct an independent review of journals seeking to participate in PMC. This was in response to a significant increase in new publishers and journals applying to participate in PMC, many of which are unknown to NLM in terms of quality and publishing practices. The independent review, which was approved by the PMC National Advisory Committee (see minutes from June 10, 2014), follows an assessment by NLM that the journal meets NLM’s criteria for its collection, as outlined in the Collection Development Manual.

PMC also recently updated the minimum requirement on the number of substantive, peer-reviewed articles needed before a journal can apply to PMC. The new 25-article minimum ensures that the reviewers have a sufficient amount of content on which to base their recommendation for inclusion in PMC. The new minimum article requirement takes effect on January 1, 2016. Publishers are encouraged to use the 25-article minimum as a guideline in the interim when submitting applications.

PMC has reorganized its FTP Service site for users interested in accessing the Text Mining Collections, which include the original Open Access (OA) Subset. New top-level FTP directories help users quickly locate the content available for bulk download that best suits their research needs. These directories include:

• oa_package - article packages for individual OA articles
• oa_pdf – individual PDFs for OA articles
• oa_bulk – bulk packages of text from OA articles
• manuscript – author manuscripts collected under a funding agency’s public access policy
• historical_ocr – select OCR texts from the PMC Back Issue Digitization project

To make it easier for users to identify and comply with the different licenses that apply to OA articles, new file lists have been created and the file lists for individual OA articles now include a “license-type” field for each article. Similarly, the bulk packages of OA article text have been divided into two sets. One set comprises articles that may be used for commercial purposes (the Commercial Use Collection); the other contains articles that can be used only for non-commercial purposes. See the Open Access Subset page for details.

To allow regular users to transition to the new arrangement, the previous arrangement of files and directories will be maintained in parallel for at least four weeks (i.e., until the end of August 2016).

As of August 2016, PMC is home to four million articles! To make this wealth of full-text content easier to navigate, PMC has rolled out a few updates:

1) Search Result Filters
On all search results pages, you will now see filters (similar to PubMed’s filters) on the left-hand side that allow you to filter your results by article attributes, publication date, research funder, and search fields. These filters replace the Limits page and allow you to more readily:

• find open access articles (PMC has more than 1.35 million open access articles that can be reused according to their license statements),
• explore PMC’s rich historical content from NLM's back issue digitization project,
• browse research supported by PMC-participating funding organizations (click "Customize" to view additional funder options),
• and much more.

You can now also quickly add articles that are under a 12-month or less embargo in PMC to your search results by selecting the “Include embargoed articles” filter option under Text Availability. See the PMC User Guide for more information on these filters.

2) Reference List Display
Using related article data available in PMC, articles that cite papers that have been either retracted or named in a Findings of Research Misconduct issued by the HHS Office of Research Integrity and not yet retracted will now include a red hyperlink to the relevant notice directly from the article’s reference list. This update will help users more easily identify post-publication updates to existing research.

In response to the growing interest in the availability of data associated with articles, PMC is reviewing current practices around data and seeking feedback on how to best serve the data needs of the research community.

As part of these efforts, the PMC policy statement on supplementary data was recently updated to more clearly articulate the requirement that any supplementary data (images, tables, video, or other documents / files) that are associated with an article must be deposited in PMC with an article. The search filter "has suppdata[filter]" can be used in PMC to discover records with associated supplementary data files.

In addition to providing supplementary data with an article, NLM is also encouraging journals and authors to make research data available in a public repository and include the relevant data citation(s) in the paper. Guidance for PMC data providers on tagging data citations is available in the Tagging Guidelines. This guidance is based on the JATS4R recommendations on data citations.

Starting this month, the NIH Manuscript Submission (NIHMS) system will also accept deposits of small datasets accompanying deposits of funded author manuscripts for inclusion of PMC. (Guidance for authors is available in the NIHMS FAQ.)

If you have suggestions on future directions in data for PMC to consider, please let us know at pubmedcentral@ncbi.nlm.nih.gov.

PMC Canada, sponsored by the Canadian Institutes of Health Research (CIHR), with operational support provided by the National Research Council (NRC), has been a valued partner in the PMC International network since 2009. CIHR and NRC have now notified NLM of their decision to permanently take PubMed Central Canada (PMC Canada) offline on February 23, 2018. Details of this decision are available on the PMC Canada website.

The decision to decommission PMC Canada does not affect the status or operations of NIH’s PubMed Central (US) or Europe PubMed Central. PMC Canada content will remain in the PMC archive and be publicly searchable on NLM’s PubMed Central (US) and through Europe PMC. CIHR researchers who publish in journals that deposit their articles directly into NIH’s PubMed Central or deposit manuscripts co-funded with current PMC-participating funders will continue to be considered in compliance with the Tri-Agency Open Access Policy on Publications.

NIH and NLM have appreciated our cooperation with CIHR and NRC over the last several years and will continue to identify new opportunities to work together to support open access and research excellence.

In collaboration with Europe PMC, PMC has rolled out several updates to our article display in order to enhance the transparency and readability of the content.

Navigating from the PMC record to the PubMed record has been made easier by the addition of hyperlinked PubMed IDs (PMIDs) in the upper right-hand corner of article records. Clicking the PMID link will take you to the corresponding citation record in PubMed.

The PMC Disclaimer link has also been moved out of the Copyright and License information section for easier discovery and access. This page describes what content is included in PMC as well as other important NCBI and NLM disclaimer information.

Additionally, two changes have been implemented to improve the functionality of author names. Users can now click on an author name to view the author’s affiliation(s). Users also have the option of running a quick author name search in PMC by clicking the linked author name in “Find articles by [author name]”. In the example pictured above, the search would be for “Sawyer SL”[Author].

And finally, figures and tables have been moved inline in the article display. By moving away from the thumbnail display, PMC hopes to make it easier for users to view figure and table data as they read articles. Users may still click on the figure/table title or “Open in separate window” (as available) link for a closer look.

We hope these updates improve the overall user experience in PMC and look forward to hearing your feedback.

References

Screenshots from:

Qiao, Y., Yang, J., Liu, L., Zeng, Y., Ma, J., Jia, J., … Wang, Y. (2018). Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report. BMC Cancer, 18, 212. http://doi.org/10.1186/s12885-018-3996-3

Stabell, A. C., Meyerson, N. R., Gullberg, R. C., Gilchrist, A. R., Webb, K. J., Old, W. M., … Sawyer, S. L. (2018). Dengue viruses cleave STING in humans but not in nonhuman primates, their presumed natural reservoir. eLife, 7, e31919. http://doi.org/10.7554/eLife.31919

Both articles made available under a CC-BY license.

Looking for journal articles with associated data sets? New search filters in PMC and PubMed aim to increase the discoverability of articles with associated data information.

In PMC, users can now search on or append searches with filters to discover articles with specific types of associated data, i.e., to find

1. articles with associated supplementary material, use “has suppdata”[filter];
2. articles that include a data availability or data accessibility statement, use “has data avail”[filter]; or
3. articles that include data citation(s), use “has data citations”[filter]

Alternatively, users can run a search on “has associated data”[filter] to find all articles with any type of data section described above.

In PubMed, users can now search on or append searches with data[filter] to find articles with related data links in either the Secondary Source ID field or the LinkOut – Other Literature Resources field (both located below the abstract). These data links may be to records in other NLM databases (e.g., GenBank) or external data repositories (e.g., figshare, Dryad).

The provision and availability of associated datasets still varies widely from article to article, but it is our hope that this small step helps improve the discoverability of this material and supports wider community efforts to advance science in new directions.

PMC has released expanded information about its selection process for journals that apply for participation. The current review process has been in place since November 2014 and focuses on the scientific rigor and editorial quality of each journal that applies to participate in PMC. Some of the attributes taken into account as part of this process include the article content, journal policies, language quality, and presentation of content. The same assessment considerations are used for reevaluation of currently participating journals. We encourage you to visit the Journal Selection for PMC page to learn more.

Publishers and journals interested in submitting an application to PMC are also encouraged to review our updated policies on agreement types. These policies provide the eligibility criteria for each type of participation agreement and should be considered alongside the pre-application requirements.

We hope these updates are informative and look forward to hearing your feedback.

In the NLM Strategic Plan released earlier this year, we noted that “[c]reating efficient ways to link the literature with associated datasets enables knowledge generation and discovery.” To that end, PMC is now aggregating data citations, data availability statements and supplementary materials, as available, in an Associated Data box. This box will only display on articles that have one or more of these features in the article.

To limit your search to records with an Associated Data box, you can use the new "Associated Data" facet on the search results page:

We hope that exposing this content in a consistent format and in an easy to find and easy to access manner, you will more readily find the datasets you need to further accelerate discovery and advance health. As part of our ongoing commitment to making data findable, accessible, interoperable, and re-usable (FAIR), we encourage you to contact us with your feedback on these updates and with any other suggestions you may have for improving discovery of related data in PMC.

Machine-readability of scholarly outputs is critical to supporting large-scale analysis of the scientific literature. To that end, PMC’s Tagging Guidelines and internal processes have been updated to support the JATS4R recommendations for tagging clinical trial information. NLM encourages PMC-participating publishers, journals, and data providers to review this guidance. Please contact us at pubmedcentral@ncbi.nlm.nih.gov if you have any questions.

Peer review documents, including review reports and editor decision letters, are increasingly being published along with the articles they review. This practice is intended to make the publishing process more transparent. To support these efforts, PMC’s Tagging Guidelines have been updated to include the tagging of peer review documents. NLM encourages PMC-participating publishers, journals, and data providers to review this guidance. Please contact us at pubmedcentral@ncbi.nlm.nih.gov if you have any questions.

Title: How Many Steps Per Day to Lengthen Your Life?
Category: Health News
Created: 3/24/2020 12:00:00 AM
Last Editorial Review: 3/25/2020 12:00:00 AM

Title: Daily Aspirin Won't Stop Dementia, Study Finds
Category: Health News
Created: 3/25/2020 12:00:00 AM
Last Editorial Review: 3/26/2020 12:00:00 AM

Title: Prescription-Strength Steroid Creams Sold Over-the-Counter Can Be Dangerous
Category: Health News
Created: 1/23/2020 12:00:00 AM
Last Editorial Review: 1/24/2020 12:00:00 AM

Title: Cialis (tadalafil) vs. Viagra (sildenafil)
Category: Medications
Created: 10/30/2017 12:00:00 AM
Last Editorial Review: 2/12/2020 12:00:00 AM

Title: Blood Pressure Dips Upon Standing Might Not Be as Dangerous as Thought
Category: Health News
Created: 1/28/2020 12:00:00 AM
Last Editorial Review: 1/29/2020 12:00:00 AM

Title: 'Couch Potato' Lifestyle Poses Danger to Women's Hearts
Category: Health News
Created: 2/18/2020 12:00:00 AM
Last Editorial Review: 2/19/2020 12:00:00 AM

Title: AHA News: Domestic Abuse May Do Long-Term Damage to Women's Health
Category: Health News
Created: 2/18/2020 12:00:00 AM
Last Editorial Review: 2/19/2020 12:00:00 AM

Title: Solosec (secnidazole)
Category: Medications
Created: 4/17/2020 12:00:00 AM
Last Editorial Review: 4/17/2020 12:00:00 AM

Title: AHA News: Make Mother's Day Last All Year With Wellness and Appreciation
Category: Health News
Created: 4/29/2020 12:00:00 AM
Last Editorial Review: 4/30/2020 12:00:00 AM

Title: How Dangerous Is General Anesthesia?
Category: Procedures and Tests
Created: 3/5/2020 12:00:00 AM
Last Editorial Review: 4/7/2020 12:00:00 AM

Title: Sinus Headache Pain, Symptoms, Treatments, Remedies, and Cures
Category: Diseases and Conditions
Created: 1/11/2010 12:00:00 AM
Last Editorial Review: 1/13/2020 12:00:00 AM

Title: First Treatment for Peanut Allergy Approved by FDA
Category: Health News
Created: 2/3/2020 12:00:00 AM
Last Editorial Review: 2/3/2020 12:00:00 AM

Title: Allergy Med Singulair to Get 'Black Box' Warning Over Psych Side Effects: FDA
Category: Health News
Created: 3/4/2020 12:00:00 AM
Last Editorial Review: 3/5/2020 12:00:00 AM

Title: FDA Warns of Defective EpiPen Dangers
Category: Health News
Created: 3/25/2020 12:00:00 AM
Last Editorial Review: 3/26/2020 12:00:00 AM

Title: Menopause May Someday Disappear as Women Postpone Pregnancy: Study
Category: Health News
Created: 4/24/2020 12:00:00 AM
Last Editorial Review: 4/27/2020 12:00:00 AM

Title: Ask Grandma to Dance to Boost Her Mood And Strengthen Your Bonds
Category: Health News
Created: 4/17/2020 12:00:00 AM
Last Editorial Review: 4/20/2020 12:00:00 AM

Title: Dangerously Hot Days for U.S. Farm Workers Could Double by 2050
Category: Health News
Created: 5/5/2020 12:00:00 AM
Last Editorial Review: 5/6/2020 12:00:00 AM

Title: FDA Approves Trodelvy for Metastatic Triple-Negative Breast Cancer
Category: Health News
Created: 4/24/2020 12:00:00 AM
Last Editorial Review: 4/24/2020 12:00:00 AM

Title: Vyxeos (daunorubicin and cytarabine)
Category: Medications
Created: 4/24/2020 12:00:00 AM
Last Editorial Review: 4/24/2020 12:00:00 AM

Title: Traveling Abroad? Make Sure Your Measles Shot Is Up to Date
Category: Health News
Created: 7/24/2019 12:00:00 AM
Last Editorial Review: 7/24/2019 12:00:00 AM

KRAS mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target. Pelareorep, a double-stranded RNA virus selectively replicates in KRAS-mutated cells, and is synergistic with irinotecan. A dose escalation trial of FOLFIRI/bevacizumab [irinotecan (150–180 mg/m²) and pelareorep (1 x 10¹⁰ TCID₅₀–3 x 10¹⁰ TCID₅₀)] was implemented in adult patients with oxaliplatin refractory/intolerant, KRAS-mutant mCRC. Pelareorep was administered intravenously over 1 hour on days 1–5 every 4 weeks. Additional studies included pharmacokinetics, tumor morphology, and immune responses. Among FOLFIRI-naïve patients, the highest dose of FOLFIRI/bevacizumab (180 mg/m² irinotecan) and pelareorep (3 x 10¹⁰ TCID₅₀) was well tolerated, without a dose-limiting toxicity. At the recommended phase II dose, 3 of 6 patients (50%) had a partial response; the median progression-free and overall survival (PFS, OS) were 65.6 weeks and 25.1 months, respectively. Toxicities included myelosuppression, fatigue, and diarrhea. Transmission electron microscopy revealed viral factories (viral collections forming vesicular structures), at various stages of development. Immunogold staining against viral capsid -1 protein demonstrated viral "homing" in the tumor cells. The nucleus displayed sufficient euchromatin regions suggestive of active transcription. Flow cytometry revealed rapid dendritic cell maturation (48 hours) with subsequent activation of cytotoxic T cells (7 days). The combination of pelareorep with FOLFIRI/bevacizumab is safe. The PFS and OS data are encouraging and deserve further exploration. Pelareorep leads to a clear recurrent immune stimulatory response with cytotoxic T-cell activation, and homes and replicates in the tumor.